Literature DB >> 6692941

Modification of the blood-brain barrier in the chemotherapy of malignant brain tumors.

E A Neuwelt, S I Rapoport.   

Abstract

Inadequate drug delivery to the brain, caused by an intact or partially intact blood-brain barrier (BBB), probably accounts for poor therapeutic responsiveness to cytoreductive drugs by malignant metastatic and primary brain tumors. Drug delivery can be enhanced in normal brains and brains with tumors by administering drugs into the carotid or vertebral circulation after osmotic opening of the BBB. The osmotic procedure in humans involves infusion into the carotid or vertebral arteries of a 25% mannitol solution for 30 s. The procedure is reversible, can be accomplished without long-term neurological deficits, and can be monitored in dogs and humans by means of enhanced computerized tomography. Osmotic BBB disruption, when combined with multiple drug administration, has proved effective in treating brain tumors in a small number of clinical cases.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6692941

Source DB:  PubMed          Journal:  Fed Proc        ISSN: 0014-9446


  29 in total

Review 1.  The blood-brain barrier: bottleneck in brain drug development.

Authors:  William M Pardridge
Journal:  NeuroRx       Date:  2005-01

Review 2.  Getting into the brain: approaches to enhance brain drug delivery.

Authors:  Mayur M Patel; Bhoomika R Goyal; Shraddha V Bhadada; Jay S Bhatt; Avani F Amin
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749

Review 3.  Bioengineered probes for molecular magnetic resonance imaging in the nervous system.

Authors:  Vivian Hsieh; Alan Jasanoff
Journal:  ACS Chem Neurosci       Date:  2012-07-11       Impact factor: 4.418

Review 4.  Blood-brain barrier and new approaches to brain drug delivery.

Authors:  W M Pardridge; R J Boado; K L Black; P A Cancilla
Journal:  West J Med       Date:  1992-03

5.  Influence of mannitol on the penetration of teicoplanin into infected CSF of experimental Staphylococcus aureus meningitis of rabbits.

Authors:  G Manquat; J P Stahl; I Pelloux; M Micoud
Journal:  Infection       Date:  1990 Mar-Apr       Impact factor: 3.553

6.  The unit impulse response procedure for the pharmacokinetic evaluation of drug entry into the central nervous system.

Authors:  J B van Bree; A V Baljet; A van Geyt; A G de Boer; M Danhof; D D Breimer
Journal:  J Pharmacokinet Biopharm       Date:  1989-08

7.  MRI-based detection of alkaline phosphatase gene reporter activity using a porphyrin solubility switch.

Authors:  Gil G Westmeyer; Yelena Emer; Jutta Lintelmann; Alan Jasanoff
Journal:  Chem Biol       Date:  2014-03-06

8.  Characterization of a new model of GM2-gangliosidosis (Sandhoff's disease) in Korat cats.

Authors:  E A Neuwelt; W G Johnson; N K Blank; M A Pagel; C Maslen-McClure; M J McClure; P M Wu
Journal:  J Clin Invest       Date:  1985-08       Impact factor: 14.808

9.  Transferrin-antibody fusion proteins are effective in brain targeting.

Authors:  S U Shin; P Friden; M Moran; T Olson; Y S Kang; W M Pardridge; S L Morrison
Journal:  Proc Natl Acad Sci U S A       Date:  1995-03-28       Impact factor: 11.205

10.  Influence of C6 and CNS1 brain tumors on methotrexate pharmacokinetics in plasma and brain tissue.

Authors:  Sylvain F Dukic; Matthieu L Kaltenbach; Tony Heurtaux; Guillaume Hoizey; Aude Lallemand; Richard Vistelle
Journal:  J Neurooncol       Date:  2004 Mar-Apr       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.